Morgan Stanley raises Carvana stock price target on strong growth By Investing.com

Morgan Stanley raised its Carvana price target to $510 from $450 and maintained an Overweight rating, citing strong profitable growth, a clean earnings beat, and momentum into FY26. Carvana posted 49% revenue growth over the last twelve months, EBITDA of $2.16 billion, and Q1 2026 EPS of $1.69 versus $1.56 expected, while revenue came in at $6.43 billion versus $6.02 billion consensus. The main offset is higher capex and valuation concerns, with the stock still trading at 27.9x EV/EBITDA even as several other brokers also lifted targets.

Analysis

The cleanest second-order read is that the market is rewarding execution while still underpricing how much operating leverage is left in CVNA if unit growth holds and fixed-cost absorption continues to improve. The bigger signal for the ecosystem is that upward estimate revisions are now coming from multiple sell-side shops at once, which tends to shorten the time between a beat and the next leg of multiple expansion; that usually matters more than the absolute earnings number in names with a heavy momentum shareholder base.

The risk is not a near-term demand miss so much as a valuation air pocket if growth normalizes before the Street finishes pushing estimates out to 2027. At nearly 28x EV/EBITDA, CVNA is already being treated like a quasi-platform asset; if retail unit growth decelerates even modestly over the next 1-2 quarters, the stock can de-rate faster than EBITDA can catch up. That makes the next catalyst window crucial: guidance commentary, unit growth trajectory, and gross profit per unit over the next two prints are likely to determine whether this becomes a durable re-rating or just another crowded momentum leg.

MS looks like the cleaner beneficiary on the flow side: when a high-profile analyst firm raises its target and ties it to visible earnings revisions, it reinforces the franchise’s credibility with growth investors and can attract incremental banking/prime-mandate flows. By contrast, JPM is the structural loser in the framing because the market is primed to extrapolate the downgrade as a signal that lenders/market-sensitive financials are facing an increasing hurdle rate for capital-market optimism, even if the macro backdrop is unchanged. The contrarian view is that consensus may be overestimating how long the market will pay for 'good news' in a highly owned winner—if CVNA’s next report is merely in-line, the stock could underperform despite fundamentals still looking strong.

Key Decisions for Investors

• Stay long CVNA only tactically, not structurally: own into the next 1-2 earnings/guidance windows, but trim strength if the stock re-rates faster than FY27 EBITDA estimates, since upside is now more dependent on multiple than fundamentals.
• Buy CVNA downside protection via put spreads 8-12 weeks out; the risk/reward favors hedging because a modest slowdown in retail unit growth could trigger a 15-25% de-rating from an already elevated EV/EBITDA base.
• Pair trade: long MS / short JPM over the next 1-3 months. The setup favors MS as a flow beneficiary of visible estimate revisions, while JPM is more exposed to the market’s negative read-through from the downgrade narrative.
• For higher-conviction traders, use CVNA call spreads rather than stock for the next leg higher. The catalyst is still real, but with multiple expansion already in motion, capped-risk upside is preferable to outright exposure.
• Watch for a reversal trigger in CVNA if consensus stops moving up after the next print. If revisions flatten while price continues to rise, take profits aggressively; the stock’s biggest downside historically is when momentum outpaces estimate momentum.